

9 March 2021

DeepMatter Group plc

("DeepMatter", the "Company" or "the Group")

Directorate Change

DeepMatter (AIM: DMTR), the AIM-quoted company focusing on digitising chemistry, is pleased to announce that Mirko Walter has been appointed to the Board as Non-Executive Director with immediate effect.

Mirko is currently Vice President Sales of Springer Nature, the global academic publishing company, and has been with the business for six years, supporting the Company's growth strategy through sales excellence, partnerships and portfolio expansion. In addition to his achievements in implementing and executing on sales strategies, Mirko has 18 years' experience working with customers to optimise their Research & Development processes and investments. Prior to joining Springer Nature, he was Head of Business Development at digital healthcare provider DocMorris, whilst it was part of McKesson Corporation, a leading company in the healthcare sector.

Mirko succeeds Bettina Goerner, who has stepped down from her operational role at Springer Nature, and therefore will step down from the DeepMatter Board effective today. Bettina joined the DeepMatter Board in March 2019, as part of the acquisition of InfoChem GmbH ("InfoChem") from Springer Nature. The Board thanks Bettina for her contribution to DeepMatter and oversight of the successful integration of the InfoChem business into the Group and wishes her all the very best for the future.

Mark Warne, Chief Executive Officer of DeepMatter commented: *"I am delighted to welcome Mirko to the Board. Mirko's passion for working with customers to create innovation based on trusted information and leading data products coupled with his wealth of experience in sales and the scientific sector will resonate with DeepMatter's long-term strategic goal to commercialise the digitisation of chemistry. We look forward to working with Mirko as we scale up the business and enter new territories. We are grateful for the contribution Bettina made in the two years since the InfoChem acquisition and wish her all the very best for the future."*

Mirko Walter, aged 40, holds no other listed company directorships, nor has he held any directorships during the five years prior to his appointment. He holds no interest in the ordinary shares of the Company. There are no further disclosures to be made in accordance with Rule 17 and paragraph (g) of Schedule 2(g) of the AIM Rules for Companies.

For more information, please contact:

DeepMatter Group plc

Mark Wame, Chief Executive Officer

T: 0141 548 8156

Canaccord Genuity Limited (Nominated Advisor and Broker)

Bobbie Hilliam / Angelos Vlatakis

T: 020 7523 8000

Alma PR

Caroline Forde / Harriet Jackson / Kieran Breheny
/ Faye Callow

T: 020 3405 0205

deepmatter@almapr.co.uk

About DeepMatter Group plc

DeepMatter's long term strategy is to integrate chemistry with technology, thereby enabling a greater use of artificial intelligence and reaching a point where chemicals can be autonomously synthesised through robotics. It has developed and is commercialising data rich platform technologies, including software and laboratory hardware, focused on applications to improve R&D productivity and discovery using Machine Learning / Artificial

Intelligence.

DeepMatter's technologies allow chemistry experiments to be accurately and systematically recorded, coded and entered into a shared data cloud. They are designed to enable chemists to work together effectively; sharing the details of their experiments from anywhere and in real-time, so that work is not needlessly duplicated, time and money wasted, and ultimately so new discoveries may be made faster.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAUPUBGWUPGPWR